Is Novartis AG (NVS) stock underpriced in the market | Underperforming - Accumulation

Market Context

Recent trading volume for NVS has been consistent with average activity for the large-cap pharmaceutical sector, with no unusual spikes or sustained below-average volume recorded this month. The broader pharma sector has seen mixed sentiment recently, as investors weigh potential upside from new drug pipeline approvals and expanded access to existing therapies against ongoing concerns around pricing regulatory pressures in key global markets. Novartis AG has moved largely in line with its large-cap pharma peer group in recent weeks, with a beta closely aligned to the sector average, meaning broader sector inflows or outflows could have a material impact on NVS’s near-term price trajectory. Macro factors, including shifting interest rate expectations, are also contributing to sentiment for defensive sectors like pharmaceuticals, as investors adjust positioning based on anticipated monetary policy moves in upcoming months. Scenario analysis based on historical volatility informs strategy adjustments. Traders can anticipate potential drawdowns and gains.

Technical Analysis

At its current trading price, NVS sits squarely between its key near-term support and resistance levels. The established support level of $145.71 has held up in multiple tests over recent weeks, with buyers stepping in to limit downside moves each time the stock has approached this threshold. On the upside, the near-term resistance level of $161.05 has acted as a consistent ceiling for price action, with sellers entering the market to cap gains on each recent attempt to move above this marker. Momentum indicators for NVS, including the relative strength index (RSI), are currently in the mid-40s, a neutral range that signals the stock is neither overbought nor oversold at current price levels. The stock is also trading between its short-term and medium-term moving averages, confirming the lack of a strong directional trend in recent weeks, with sideways price action dominating. Volatility for NVS has remained relatively muted compared to broader equity benchmarks, consistent with the defensive profile of large pharmaceutical names. Some investors integrate technical signals with fundamental analysis. The combination helps balance short-term opportunities with long-term portfolio health.

Outlook

There are two key potential scenarios for NVS in the near term, based on current technical levels. If Novartis AG is able to test and break above the $161.05 resistance level on above-average volume, this could potentially open the door to moves toward upper prior trading ranges, with momentum flows possibly supporting further upside if the breakout is sustained. On the downside, a break below the $145.71 support level on elevated volume could lead to a potential retracement to lower support zones, with selling pressure possibly accelerating if the level is convincingly breached. In the absence of major sector or company-specific catalysts, analysts estimate that NVS would likely continue to trade within the established support and resistance range in the near term. Investors are monitoring upcoming regulatory updates for pharmaceutical products and potential pipeline announcements from Novartis AG, which could act as catalysts to drive a breakout from the current trading range. Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Tracking global futures alongside local equities offers insight into broader market sentiment. Futures often react faster to macroeconomic developments, providing early signals for equity investors.